COMMAND DASHBOARD
Company snapshot: $70M Series C funding, 90 employees, revenue/ARR undisclosed. Healthcare clinical AI assistant focused on ambient documentation with integrations across Epic, Cerner, athenahealth, and NextGen EHRs.
Bottom-up to enterprise friction: Product-led motion with free tier and $119/month individual subscriptions triggering enterprise contracts through grassroots adoption, creating friction in lead routing, attribution, and expansion forecasting.
Competitive commoditization risk: Crowded ambient scribe category with Microsoft Nuance DAX, Abridge, Suki, Ambience competing on EHR depth and enterprise readiness. Head-to-head pilots lengthen sales cycles and increase conversion complexity.
ROI expansion pressure: Positioning into coding/revenue-cycle workflows (ICD-10/HCC/MCC, E/M guidance) to quantify billing accuracy impact beyond documentation efficiency, implying need for measurable revenue impact.
EHR deployment complexity: Managing heterogeneous EHR environments creates RevOps pain around pipeline segmentation by integration readiness and implementation-driven revenue recognition across major health systems.
Product perception gaps: Some clinician feedback frames Nabla as "simple/bare-bones" versus alternatives with more control/specialty options, creating retention/expansion risk and need for competitive enablement.

Nabla's enterprise motion relies on organic bottom-up conversion without systematic qualification or EHR-specific playbooks. No structured approach exists to convert individual clinician adoption into health system contracts, leaving revenue dependent on grassroots momentum rather than controlled enterprise sales processes. The cost of staying here: losing enterprise deals to competitors with deeper EHR integration narratives while struggling to prove ROI beyond time savings.

Days 1–90Q1 — FOUNDATION
Days 91–180Q2 — BUILD
Days 181–270Q3 — SCALE
Days 271–365Q4 — OPTIMIZE
Conservative

$12M new enterprise ARR

Target

$18M new enterprise ARR

Stretch

$25M new enterprise ARR (assumes 3 large health system platform deals above $500K ACV)

Strategic Summary

Nabla has strong product-market fit in ambient clinical documentation but lacks enterprise revenue infrastructure to convert bottom-up adoption into systematic health system contracts. The crowded competitive landscape and commoditization risk require EHR-specific differentiation and ROI quantification beyond time savings. Building systematic enterprise conversion processes with partner channel leverage can generate $12M-$25M in new ARR while establishing defensible competitive positioning in the ambient scribe market.

Production systems, not theory. Revenue captured, not demos given.